Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Read about Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Read about Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Read about Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Read about Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Read about Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
Read about Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
Read about Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024
Read about Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024